Skip to main content
Paul Carpenter, MD, Pediatric Hematology & Oncology, Seattle, WA

PaulAndrewCarpenterMD

Pediatric Hematology & Oncology • Seattle, WA

Physician

Join to view full profile

Dr. Carpenter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Carpenter's full profile

Already have an account?

  • Office

    825 Eastlake Ave E
    Seattle, WA 98109
    Phone+1 206-228-1000

Education & Training

  • University of Sydney Faculty of Medicine
    University of Sydney Faculty of MedicineClass of 1988

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2001 - 2025
  • AK State Medical License
    AK State Medical License 2022 - 2024

Publications & Presentations

PubMed

Press Mentions

  • FDA Approves Ibrutinib (Imbruvica) for Graft-Versus-Host Disease in Children, Young Adults
    FDA Approves Ibrutinib (Imbruvica) for Graft-Versus-Host Disease in Children, Young AdultsAugust 25th, 2022
  • (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
    (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host DiseaseAugust 24th, 2022
  • The U.S. Food and Drug Administration Approved the Use of IMBRUVICA for the Treatment of Pediatric Patients One Year and Older with cGVHD After Failure of One or More Lines of Systemic Therapy
    The U.S. Food and Drug Administration Approved the Use of IMBRUVICA for the Treatment of Pediatric Patients One Year and Older with cGVHD After Failure of One or More Lines of Systemic TherapyAugust 24th, 2022
  • Join now to see all

Dr. Paul Carpenter, Dr. Paul Carpenter, MD, Dr. P Carpenter, Dr. Paul Andrew Carpenter